In vivo inhibition of angiogenesis by sulphamoylated derivatives of 2-methoxyoestradiol

S. K. Chander, P. A. Foster, Mathew P. Leese, S. P. Newman, Barry V. L. Potter, A. Purohit, M. J. Reed

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

Drugs that inhibit growth of tumours and their blood supply could have considerable therapeutic potential. 2-Methoxyoestradiol-3,17- O,O-bis-sulphamate (2-MeOE2bisMATE) has been shown to inhibit the proliferation of MCF-7 (ER+) breast cancer cells and angiogenesis in vitro. 2-MeOE2bisMATE and its analogue, 17-Cym-2-MeOE2MATE, were investigated for their ability to inhibit in vivo angiogenesis and tumour growth. The mouse Matrigel plug assay for angiogenesis was used to investigate the effect of compounds on neovascularisation and was quantified using a FITC-dextran injection technique. Nude mice bearing tumours derived from MCF-7 cells were used to assess efficacy on tumour growth. Tumour sections were stained for VEGFR-2 and Ki67 to assess tumour angiogenesis and cell proliferation respectively. Matrigel plugs supplemented with basic fibroblast growth factor resulted in increased neovascularisation over 7 days. Oral administration of 2- MeOE2bisMATE for 7 days at 10 or 50 mg kg(-1) significantly reduced neovascularisation to or below control levels respectively. 17-Cym-2-MeOE2MATE at 20 mg kg(-1) was equally effective. 2MeOE2bisMATE, dosed daily for 21 days, caused a 52% reduction in tumour growth at 5mg kg(-1) and 38% regression at 20 mg kg(-1). 17-Cym-2-MeOE2MATE (20 mg kg(-1)) reduced tumour growth by 92%. Immunohistochemistry revealed a reduction in angiogenesis and proliferation. Matrigel plug and tumour imaging after FITC-dextran injection indicated that 2-MeOE2bisMATE caused a marked disruption of vasculature. These sulphamoylated oestrogen derivatives have been shown to be potent inhibitors of angiogenesis in vivo. This, together with their ability to inhibit tumour growth, indicates the potential of this new class of drugs for further development for cancer therapy.
Original languageEnglish
Pages (from-to)1368-1376
JournalBritish Journal of Cancer
Volume96
Issue number9
DOIs
Publication statusPublished - 2007

Fingerprint

Neoplasms
Growth
2-methoxyestradiol
Vascular Endothelial Growth Factor Receptor-2
Injections
Angiogenesis Inhibitors
MCF-7 Cells
Fibroblast Growth Factor 2
Nude Mice
Pharmaceutical Preparations
Oral Administration
Estrogens
Immunohistochemistry
Cell Proliferation
Breast Neoplasms
2-methoxyestradiol-3,17-bis-O,O-sulfamate
Therapeutics
matrigel
fluorescein isothiocyanate dextran

Cite this

Chander, S. K., Foster, P. A., Leese, M. P., Newman, S. P., Potter, B. V. L., Purohit, A., & Reed, M. J. (2007). In vivo inhibition of angiogenesis by sulphamoylated derivatives of 2-methoxyoestradiol. British Journal of Cancer, 96(9), 1368-1376. https://doi.org/10.1038/sj.bjc.6603727

In vivo inhibition of angiogenesis by sulphamoylated derivatives of 2-methoxyoestradiol. / Chander, S. K.; Foster, P. A.; Leese, Mathew P.; Newman, S. P.; Potter, Barry V. L.; Purohit, A.; Reed, M. J.

In: British Journal of Cancer, Vol. 96, No. 9, 2007, p. 1368-1376.

Research output: Contribution to journalArticle

Chander, SK, Foster, PA, Leese, MP, Newman, SP, Potter, BVL, Purohit, A & Reed, MJ 2007, 'In vivo inhibition of angiogenesis by sulphamoylated derivatives of 2-methoxyoestradiol', British Journal of Cancer, vol. 96, no. 9, pp. 1368-1376. https://doi.org/10.1038/sj.bjc.6603727
Chander, S. K. ; Foster, P. A. ; Leese, Mathew P. ; Newman, S. P. ; Potter, Barry V. L. ; Purohit, A. ; Reed, M. J. / In vivo inhibition of angiogenesis by sulphamoylated derivatives of 2-methoxyoestradiol. In: British Journal of Cancer. 2007 ; Vol. 96, No. 9. pp. 1368-1376.
@article{e24a4503c40a4e29b5d987b6ab2b7b60,
title = "In vivo inhibition of angiogenesis by sulphamoylated derivatives of 2-methoxyoestradiol",
abstract = "Drugs that inhibit growth of tumours and their blood supply could have considerable therapeutic potential. 2-Methoxyoestradiol-3,17- O,O-bis-sulphamate (2-MeOE2bisMATE) has been shown to inhibit the proliferation of MCF-7 (ER+) breast cancer cells and angiogenesis in vitro. 2-MeOE2bisMATE and its analogue, 17-Cym-2-MeOE2MATE, were investigated for their ability to inhibit in vivo angiogenesis and tumour growth. The mouse Matrigel plug assay for angiogenesis was used to investigate the effect of compounds on neovascularisation and was quantified using a FITC-dextran injection technique. Nude mice bearing tumours derived from MCF-7 cells were used to assess efficacy on tumour growth. Tumour sections were stained for VEGFR-2 and Ki67 to assess tumour angiogenesis and cell proliferation respectively. Matrigel plugs supplemented with basic fibroblast growth factor resulted in increased neovascularisation over 7 days. Oral administration of 2- MeOE2bisMATE for 7 days at 10 or 50 mg kg(-1) significantly reduced neovascularisation to or below control levels respectively. 17-Cym-2-MeOE2MATE at 20 mg kg(-1) was equally effective. 2MeOE2bisMATE, dosed daily for 21 days, caused a 52{\%} reduction in tumour growth at 5mg kg(-1) and 38{\%} regression at 20 mg kg(-1). 17-Cym-2-MeOE2MATE (20 mg kg(-1)) reduced tumour growth by 92{\%}. Immunohistochemistry revealed a reduction in angiogenesis and proliferation. Matrigel plug and tumour imaging after FITC-dextran injection indicated that 2-MeOE2bisMATE caused a marked disruption of vasculature. These sulphamoylated oestrogen derivatives have been shown to be potent inhibitors of angiogenesis in vivo. This, together with their ability to inhibit tumour growth, indicates the potential of this new class of drugs for further development for cancer therapy.",
author = "Chander, {S. K.} and Foster, {P. A.} and Leese, {Mathew P.} and Newman, {S. P.} and Potter, {Barry V. L.} and A. Purohit and Reed, {M. J.}",
year = "2007",
doi = "10.1038/sj.bjc.6603727",
language = "English",
volume = "96",
pages = "1368--1376",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Research",
number = "9",

}

TY - JOUR

T1 - In vivo inhibition of angiogenesis by sulphamoylated derivatives of 2-methoxyoestradiol

AU - Chander, S. K.

AU - Foster, P. A.

AU - Leese, Mathew P.

AU - Newman, S. P.

AU - Potter, Barry V. L.

AU - Purohit, A.

AU - Reed, M. J.

PY - 2007

Y1 - 2007

N2 - Drugs that inhibit growth of tumours and their blood supply could have considerable therapeutic potential. 2-Methoxyoestradiol-3,17- O,O-bis-sulphamate (2-MeOE2bisMATE) has been shown to inhibit the proliferation of MCF-7 (ER+) breast cancer cells and angiogenesis in vitro. 2-MeOE2bisMATE and its analogue, 17-Cym-2-MeOE2MATE, were investigated for their ability to inhibit in vivo angiogenesis and tumour growth. The mouse Matrigel plug assay for angiogenesis was used to investigate the effect of compounds on neovascularisation and was quantified using a FITC-dextran injection technique. Nude mice bearing tumours derived from MCF-7 cells were used to assess efficacy on tumour growth. Tumour sections were stained for VEGFR-2 and Ki67 to assess tumour angiogenesis and cell proliferation respectively. Matrigel plugs supplemented with basic fibroblast growth factor resulted in increased neovascularisation over 7 days. Oral administration of 2- MeOE2bisMATE for 7 days at 10 or 50 mg kg(-1) significantly reduced neovascularisation to or below control levels respectively. 17-Cym-2-MeOE2MATE at 20 mg kg(-1) was equally effective. 2MeOE2bisMATE, dosed daily for 21 days, caused a 52% reduction in tumour growth at 5mg kg(-1) and 38% regression at 20 mg kg(-1). 17-Cym-2-MeOE2MATE (20 mg kg(-1)) reduced tumour growth by 92%. Immunohistochemistry revealed a reduction in angiogenesis and proliferation. Matrigel plug and tumour imaging after FITC-dextran injection indicated that 2-MeOE2bisMATE caused a marked disruption of vasculature. These sulphamoylated oestrogen derivatives have been shown to be potent inhibitors of angiogenesis in vivo. This, together with their ability to inhibit tumour growth, indicates the potential of this new class of drugs for further development for cancer therapy.

AB - Drugs that inhibit growth of tumours and their blood supply could have considerable therapeutic potential. 2-Methoxyoestradiol-3,17- O,O-bis-sulphamate (2-MeOE2bisMATE) has been shown to inhibit the proliferation of MCF-7 (ER+) breast cancer cells and angiogenesis in vitro. 2-MeOE2bisMATE and its analogue, 17-Cym-2-MeOE2MATE, were investigated for their ability to inhibit in vivo angiogenesis and tumour growth. The mouse Matrigel plug assay for angiogenesis was used to investigate the effect of compounds on neovascularisation and was quantified using a FITC-dextran injection technique. Nude mice bearing tumours derived from MCF-7 cells were used to assess efficacy on tumour growth. Tumour sections were stained for VEGFR-2 and Ki67 to assess tumour angiogenesis and cell proliferation respectively. Matrigel plugs supplemented with basic fibroblast growth factor resulted in increased neovascularisation over 7 days. Oral administration of 2- MeOE2bisMATE for 7 days at 10 or 50 mg kg(-1) significantly reduced neovascularisation to or below control levels respectively. 17-Cym-2-MeOE2MATE at 20 mg kg(-1) was equally effective. 2MeOE2bisMATE, dosed daily for 21 days, caused a 52% reduction in tumour growth at 5mg kg(-1) and 38% regression at 20 mg kg(-1). 17-Cym-2-MeOE2MATE (20 mg kg(-1)) reduced tumour growth by 92%. Immunohistochemistry revealed a reduction in angiogenesis and proliferation. Matrigel plug and tumour imaging after FITC-dextran injection indicated that 2-MeOE2bisMATE caused a marked disruption of vasculature. These sulphamoylated oestrogen derivatives have been shown to be potent inhibitors of angiogenesis in vivo. This, together with their ability to inhibit tumour growth, indicates the potential of this new class of drugs for further development for cancer therapy.

UR - http://dx.doi.org/10.1038/sj.bjc.6603727

U2 - 10.1038/sj.bjc.6603727

DO - 10.1038/sj.bjc.6603727

M3 - Article

VL - 96

SP - 1368

EP - 1376

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 9

ER -